Durect Transforming AH Treatment with Larsucosterol’s Promise
In this interview, Jim Brown, CEO of Durect Corporation, shared insights into the treatment of Alcohol-Associated Hepatitis (AH) with...
Moe Alsumidaie
Macro Trends in Pharma: AI, Innovation, and the Impact on Outsourcing Strategy
At SCOPE Summit 2025, a panel discussion explored the industry’s macro trends, focusing on AI, innovation, and outsourcing strategies....
Hacking the Placebo Effect: How AI Is Reshaping Clinical Trial Variability
AI is making significant strides in the rapidly evolving field of clinical trials. Dominique Demolle, CEO of Cognivia, shares...
Did the FDA Just Redefine Real-World Evidence Without Telling Anyone?
Real-world evidence (RWE) is increasingly referenced in regulatory conversations, particularly following the FDA’s 2023 guidance. Roche’s recent FDA clearance...
What Experts Are Saying About RWD in Clinical Trials
At the 2025 SCOPE Summit Conference, industry leaders gathered to discuss the integration of real-world data (RWD) into clinical...
Understanding the FDA’s Draft Guidance on Protocol Deviations in Clinical Investigations
The U.S. Food and Drug Administration (FDA) has released a draft guidance document titled Protocol Deviations for Clinical Investigations of...
PathAI: Clinical Trial Pathology Revolution
In this interview, we engage with PathAI leaders: Eric Walk, MD, Chief Medical Officer; Ella Stewart, Senior Product Manager;...
Azitra: Revolutionizing Skin Disease Treatment
In this interview, Francisco Salva, CEO of Azitra, shared insights into the company’s innovative approach to treating skin diseases....
Move Over Pharma: Patient-Led Organizations Advance Rare Disease Clinical Trials
At the 2025 SCOPE Summit, industry leaders and patient advocates discussed a transformative shift in the pharmaceutical industry: patient-led...
Pharma’s Future: Graham Clark on Trends and Challenges
In the dynamic world of pharmaceuticals, staying ahead of trends and challenges is vital. Graham Clark, CEO of Phastar,...